Valuation
Is the price right?Insufficient data
Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.
Bringing the fundamentals into focus…
CANF HealthcareBeta data
Can-Fite BioPharma Ltd.
$1.62-0.61%
Price as of close on Nov 3, 2026 · Financials updated Nov 2, 2026
Basics
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Market cap
- 4.9M USD
- Enterprise value
- -3.5M USD
- Full-time employees
- 5
Growth
Is it growing?2/100
Weak
2/3 inputs reported · Partial data
Since last quarter: ▼ Weaker
- 12-month revenue fell 27.7%
Why
Compare with peers Weaker than most peers on:
- ▼ Revenue growth
- ▼ 3-yr revenue
Behind the score
Revenue and earnings-per-share growth over one year, and revenue growth over three years.
Earnings per share growthUnavailable
Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0976 · MAD: 0.29913-year revenue growth-20.6%
SEC filings · 3 years to Dec 2025Reported value33% base weight · Z-score -3.15Sector median: 0.0584 · MAD: 0.0840Revenue growth-39.9%
SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score -4.72Sector median: 0.0609 · MAD: 0.0974Profitability
Does it earn well?1/100
Weak
3/3 inputs reported · High confidence
Since last quarter: No major change
Why
Compare with peers Weaker than most peers on:
- ▼ Operating margin
- ▼ ROA
- ▼ ROIC
Behind the score
Return on invested capital, operating margin, and return on assets.
Operating margin-2456.8%
SEC filings · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217Return on assets-103.3%
SEC filings · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537Return on invested capital-12282.0%
SEC filings · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -16.87Sector median: 0.0471 · MAD: 0.1004Other data (not scored)
Gross margin100.0%
Yahoo Finance · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310Return on equity-211.4%
Yahoo Finance · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225Risk
Debt, liquidity, price swingsLower
Lower relative risk
2/3 inputs reported · Partial data
Since last quarter: No major change
Why
Compare with peers Stronger than most peers on:
- ▲ Debt / equity
- ▲ Current ratio
Behind the score
Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.
BetaUnavailable
Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380Current ratio3.60×
Yahoo FinanceReported value33% base weight · Z-score 0.73Sector median: 2.5860 · MAD: 1.3850Debt / equity0.01×
Yahoo FinanceReported value33% base weight · Z-score 1.04Sector median: 0.2215 · MAD: 0.2039Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Can-Fite BioPharma
- Is Can-Fite BioPharma getting weaker?
- Its latest SEC filing (Mar 26, 2026) got weaker in some ways: 12-month revenue fell 27.7%. Its overall score is unchanged at 27/100 since Oct 28, 2026.
- How is Can-Fite BioPharma valued vs its peers?
- Insufficient data: 1 of 3 inputs reported (at least 2 needed).
- Is Can-Fite BioPharma growing?
- More slowly than most of its peers. Growth scores 2/100 against 1,393 healthcare peers. Revenue growth -39.9% vs a peer median of 6.1% (weaker than 95% of peers).Revenue growth -39.9% vs peers 6.1% (weaker than 95% of peers).
- How profitable is Can-Fite BioPharma?
- Less profitable than most of its peers. Profitability scores 1/100 against 1,393 healthcare peers. Operating margin -2456.8% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -2456.8% vs peers 7.1% (weaker than 100% of peers).
- How risky is Can-Fite BioPharma?
- Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.01× vs a peer median of 0.22× (stronger than 89% of peers).Debt / equity 0.01× vs peers 0.22× (stronger than 89% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Dec 31, 2025 · filed Mar 26, 2026 · compared with the quarter ended Jun 30, 2025Got weaker
- 12-month revenue fell 27.7%
Worth watching: Can-Fite BioPharma is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.
| Previous quarter | Latest quarter | Change | |
|---|---|---|---|
| Revenue (12 months) | 560,000 USD | 405,000 USD | −27.7% |
| Net income (12 months) | −8.8M USD | −9.8M USD | +11.7% |
| Operating margin | -1595.4% | -2456.8% | −861.4 pts |
| Free cash flow (12 months) | −8.4M USD | −9.0M USD | +7.1% |
| Cash | 6.5M USD | 5.5M USD | −14.3% |
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Financials
Fiscal years from SEC annual filings · change vs the prior year| Key ratios | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | Change |
|---|---|---|---|---|---|---|
| Operating margin | -1505.5% | -1246.4% | -1103.0% | -1206.2% | -2456.8% | ▼ >999 pts |
| Net margin | -1478.9% | -1255.9% | -1027.5% | -1169.1% | -2426.7% | ▼ >999 pts |
| Return on assets (ROA) | -62.3% | -109.6% | -76.4% | -86.4% | -103.3% | ▼ 17 pts |
| Return on equity (ROE) | -87.7% | -227.5% | -122.3% | -145.0% | -175.8% | ▼ 31 pts |
| Free cash flow margin | -1157.0% | -1334.6% | -1136.2% | -1133.8% | -2210.1% | ▼ >999 pts |
| Current ratio | 7.35× | 3.66× | 4.90× | 4.38× | 3.46× | ▼ 21% |
| Interest coverage | — | -45.48× | -16.20× | -27.94× | -35.04× | ▼ 25% |
CANF price history
Price history is added with the daily price update and will appear after the next one.